Vir Biotechnology reported Q3 2026 financial results

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026.¹ A copy of the press release is furnished herewith as Exhibit 99.1² and is incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934³, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release of the Company, dated November 4 , 2026⁴

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)⁴

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIR BIOTECHNOLOGY, INC.

Date: November 4, 2026

By: /s/ Aziz Sawaf⁵

Aziz Sawaf, MBEE, MBA, CFA⁵

Executive Vice President and Chief Financial Officer⁵

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

- VIR-5500 received Fast Track designation and achieved proof of concept, with pivotal trials to begin next year

- Entered collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked T-cell engager development candidates⁷

- Ended quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront consideration from the Gilead collaboration⁶

- Conference call scheduled for November 4, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

SAN FRANCISCO, November 4, 2026 - Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026.

"We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. "We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders."

Pipeline Programs

Chronic Hepatitis Delta (CHD)

• The Company will present expanded Phase 2 SOLSTICE results in oral presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2026 on November 8.

• Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026. ECLIPSE 1 is a Phase 3 trial evaluating the safety and efficacy of monthly subcutaneous administration of elebsiran and tobevibart compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited.

• Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.

• Data from ECLIPSE 1, ECLIPSE 2 and ECLIPSE 3 will be part of a comprehensive global filing package.

Oncology

VIR-5500/ ASP6958

• U.S. FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC).

• VIR-5500 has achieved proof of concept, reinforcing the scientific rationale for advancing the program into late-stage development. The Company expects multiple pivotal trials to begin in 2027.

• VIR-5500 is currently being evaluated in a Phase 1 trial (NCT05997615) as a monotherapy and combination therapy across six dose expansion cohorts. Indications include taxane naïve mCRPC, radioligand therapy naïve mCRPC, radioligand therapy exposed mCRPC and metastatic hormone sensitive prostate cancer (mHSPC).

VIR-5818

• The Phase 1 trial (NCT05356741) evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, safety and pharmacokinetics, with dose escalation and signal-finding components, has enrolled patients with a variety of HER2-expressing cancers. Following recent feedback from the FDA, the Company intends to add backfill cohorts in a more homogeneous patient population in the monotherapy arm of the study to determine optimal dose and schedule. This is aligned with the FDA's Project Optimus, an initiative to reform the dose optimization and dose selection paradigm in oncology drug development.

• Dose escalation of VIR-5818 in combination with pembrolizumab, a PD1 inhibitor, is ongoing.

• The Company expects to present data at a future scientific conference.

VIR-5525

• The Phase 1 trial (NCT06960395) of VIR-5525, an EGFR-targeted PRO-XTEN ® dual-masked TCE, continues enrollment as expected, both as a monotherapy and in combination with pembrolizumab.

Preclinical Pipeline Candidates

• The Company plans to host a virtual research investor event during the first quarter of 2027 to provide investors with a comprehensive view of its oncology strategy, including information on new development candidates from its preclinical pipeline.

• The Company announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked TCE development candidates targeting selected solid tumor-associated antigens. Under the agreement, Gilead will have an exclusive license to develop and commercialize the novel TCEs.

o The Company received $90 million in cash consideration, including a $65 million upfront payment and a $25 million equity investment at a 30% premium, and is eligible to receive up to $45 million in potential near-term preclinical milestones.^{8 8}The Company also has the potential to receive up to $1.74 billion in further development, regulatory and commercial milestones⁸, along with tiered royalties on net sales.

Corporate Update

• The Company appointed Aziz Sawaf, MBEE, MBA, CFA, as its Executive Vice President and Chief Financial Officer.

• The Company appointed David Liu, M.D., Ph.D., as its Executive Vice President and Chief Medical Officer.

• The Company appointed Suzanne Topalian, M.D.,